Now showing items 1-3 of 3
Sustained efficacy and safety of agomelatine versus placebo over 24 weeks in elderly out-patients suffering from major depressive disorder
With an increasingly ageing population, there is a growing need to develop novel ways to treat depression in the elderly. Few published placebo-controlled study results in elderly depressed patients reached a clinical ...
Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial
Background The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse effects. Preliminary evidence suggests that administering the glutamate antagonist ketamine with ECT might alleviate ...
Effect of agomelatine 25-50mg on functional outcomes in patients with major depressive disorder
Purpose: The purpose of this work is to investigate the effect of agomelatine on functioning compared with placebo in patients suffering from Major Depressive Disorder (MDD). Methods: Data from two randomized, parallel, ...